Clinical Trial

First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a single-arm, open-lable, single-center phase II clinical trial for patients with advanced or metastatic pleural mesothelioma. The aim of this study was to observe and evaluate the efficacy and safety of Sintilimab combined with Anlotinib hydrochloride and platinum-containing dual-agent chemotherapy as first-line therapy in malignant pleural mesothelioma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-12-27; most recent amendment 2025-05-27.
Status change: Not Yet Recruiting → Recruiting 2025-03-31
Trial Details
NCT Number NCT05188859
Lead Sponsor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions Mesothelioma, Malignant, Mesothelioma, Malignant Pleural, Mesothelioma Malignant Advanced
Enrollment 29 participants
Start Date 2024-09-01
Primary Completion 2026-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2025-05-31